PEDIATRICS Vol. 95 No. 2 February 1995, pp. 318
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falcini, F.
Right arrow Articles by Bartolozzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falcini, F.
Right arrow Articles by Bartolozzi, G.

Deflazacort in Pediatric Rheumatic Diseases Needs a Frequent Follow-up of Bone Densitometry

Fernanda Falcini MD1, Sandra Trapani MD1, Marialisa Ermini MD1, and Giorgio Bartolozzi MD1

1 Department of Pediatrics, University of Florence, Italy

Osteoporosis is the most important side effect of long-term steroid treatment.1 Fractures are a frequent consequence of osteoporosis and mainly affect the spine (height loss, kyphosis, severe acute or chronic back pain, and complete immobility).2 In children the management of this complication is difficult particularly when a full dose of steroids is required to control the underlying disease. Recently it has been suggested that Deflazacort (DFL), an oxazolinic acid derivative of prednisone, may have a bone sparing effect when compared with prednisone.3




This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
G. Saviola, L. Abdi. Ali, S. Shams. Eddin, A. Coppini, F. Cavalieri, L. Campostrini, S. Sacco, M. Bucci, G. Cirino, and M. Rossini
Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study
Rheumatology, June 1, 2007; 46(6): 994 - 998.
[Abstract] [Full Text] [PDF]